Cue Biopharma is trading 11.33% higher at $34.40 as investors continue reacting to positive CUE-221 Phase 2 results announced September 20, 2026. - The study met its primary and key secondary endpoints, with favorable safety results and sustained benefit versus omalizumab. - Shares gained 9.30% on September 22 after falling 23.70% on September 21. Broader biotech strength, with XBI up 2.07%, is also providing support.